Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access
Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc
Journal website

Original Article

Volume 1, Number 1, April 2011, pages 14-20

Characteristics of Graves’ Disease in a Cohort of Chronic Hepatitis C Patients Treated With Interferon-α and Ribavirin


Figure 1.
Figure 1. Schematic summaries of the cases and their final thyroid outcomes. The arrow bars indicate the duration of combination therapy with interferon-α and ribavirin. See text for detailed discussions.


Table 1. Characteristics and Long Term Follow-up of 5 Patients Who Developed Graves’ Disease in Conjunction With Interferon-α and Ribavirin Therapy
Subject No.Gender/AgeEthnicityTreatment DurationThyroid ScanFinal DiagnosisTreatmentLong Term Outcome (12 months after end of treatment)
CBZ, Carbimazole.
1F/53C16Toxic nodule & diffuse uptake 6%Mixed Graves’ disease and toxic solitary noduleCBZ for 6 monthsEuthyroidism
2M/47C488% diffuse uptakeGraves’ diseaseCBZ for 6 monthsEuthyroidism
3Phase 1 (thyroiditis phase)Negligible uptakeTriphasic thyroiditis, Graves’ diseaseSymptomatic treatmentEuthyroidism
Phase 2 (thyrotoxic phase)5% diffuse uptakeCBZ for 6 months
4Phase 1 (thyroiditis phase)Negligible uptakeTriphasic thyroiditis, Graves’ diseaseSymptomatic treatmentEuthyroidism
Phase 2 (thyrotoxic phase)8% diffuse uptakeCBZ for 6 months
5F/49C489% diffuse uptakeGraves’ diseaseCBZ for 12 monthsEuthyroidism


Table 2. Thyroid Autoantibody Profiles Before and After Thionamide Therapy in the Five Cases
Subject No.Anti-thyroglobulinAnti-thyroperoxidasehTRAb
The ‘After’ antibody levels are measured after 6 months (at the end) of therapy.
110122714130.2< 2
28111492816.6< 2
31597891176783.3< 2
422262587519.3< 2